Entero Therapeutics (FRA:366) YoY EBITDA Growth : 98.24% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Entero Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Entero Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 98.24%.

Entero Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €-0.58.

Entero Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Entero Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entero Therapeutics YoY EBITDA Growth Chart

Entero Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

67.74

-74.80

-18.84

98.51

88.77

Entero Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															98.48	96.69	-102.29	96.80	98.24

Entero Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Entero Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-42.964	-	-382.417)	/	\| -382.417 \|
=	88.77 %

Entero Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(-0.584	-	-33.211)	/	\| -33.211 \|
=	98.24 %

Entero Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Entero Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Entero Therapeutics (FRA:366) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entero Therapeutics Inc (FRA:366) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

ENTO:USA

Address

777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431

Website

https://www.firstwavebio.com

First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.

Entero Therapeutics (FRA:366) Headlines

No Headlines